CEL-SCI Corporation (CVM), based in Vienna, Virginia, is an innovative biotechnology company focused on developing immunotherapy treatments for cancer and infectious diseases. Its lead product candidate, Multikine, aims to effectively harness the immune system to target and eradicate tumors, signifying a significant advancement in cancer therapy. With a robust pipeline designed to address critical unmet medical needs, CEL-SCI is strategically positioned to transform the biopharmaceutical space, making it an attractive opportunity for institutional investors looking to support groundbreaking healthcare innovations.

NYSE MKT

USA

HEALTHCARE

BIOTECHNOLOGY

8229 BOONE BOULEVARD, VIENNA, VA, UNITED STATES, 22182

September

$46.1 Million

-$22.7 Million

0.0

-6.27

$0.00

0.0%

0.549